SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report.
Acne fulminans
Adalimumab
Depression
Hidradenitis suppurativa
Isotretinoin
Osteitis
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
13 Nov 2020
13 Nov 2020
Historique:
received:
26
03
2020
accepted:
26
10
2020
entrez:
14
11
2020
pubmed:
15
11
2020
medline:
6
10
2021
Statut:
epublish
Résumé
SAPHO (synovitis, acne, pustolosis, hyperostosis and osteitis) syndrome is a rare autoinflammatory chronic disorder, presenting with non-infectious osteitis, sterile joint inflammation and skin manifestations including palmoplantar pustolosis and severe acne. It could be often misdiagnosed for its heterogeneous clinical presentation. Treatment is challenging and, due to the rarity of this syndrome, no randomized controlled clinical trials have been conducted. Empirical treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibiotics and bisphosphonates and disease-modifying anti-rheumatic drugs (DMARDs) could be quite effective. Anti-tumor necrosis factor-alpha (anti-TNF-α) agents and interleukin-1 (IL-1) antagonists have shown promising results in refractory patients. Isotretinoin, commonly used for severe acne, has been rarely described as possible trigger of osteo-articular manifestations, in particular sacroiliitis. The case of a boy, affected by acne fulminans and depression, who presented with sacroiliitis after a 10-week treatment with isotretinoin is presented. After SAPHO diagnosis, NSAIDs therapy was started but the onset of bilateral gluteal hidradenitis suppurativa required the switch to a TNF-α antagonist (Adalimumab) with the achievement of a good control of the disease. Despite specific therapy with sertraline, the patient continued to complains severe depression. Our case reports a temporal association between the onset of osteo-articular symptoms and the introduction of isotretinoin, as previously described. However, this timeline is not sufficient to establish a causal role of this drug into the pathogenesis of sacroiliitis. At this regard, further studies are required. The occurrence of hidradenitis suppurativa during SAPHO course supported the introduction of TNF-α blockers with a favourable result, as reported in a few cases in literature. The association between SAPHO syndrome and depressive mood disorders is already reported. Our patient experienced severe depression whose trend seems to be independent from the course of the main disease. Currently, it is not clarified if depression could be considered reactive to the underling disease or if it forms an integral part of the autoinflammatory disorder.
Sections du résumé
BACKGROUND
BACKGROUND
SAPHO (synovitis, acne, pustolosis, hyperostosis and osteitis) syndrome is a rare autoinflammatory chronic disorder, presenting with non-infectious osteitis, sterile joint inflammation and skin manifestations including palmoplantar pustolosis and severe acne. It could be often misdiagnosed for its heterogeneous clinical presentation. Treatment is challenging and, due to the rarity of this syndrome, no randomized controlled clinical trials have been conducted. Empirical treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibiotics and bisphosphonates and disease-modifying anti-rheumatic drugs (DMARDs) could be quite effective. Anti-tumor necrosis factor-alpha (anti-TNF-α) agents and interleukin-1 (IL-1) antagonists have shown promising results in refractory patients. Isotretinoin, commonly used for severe acne, has been rarely described as possible trigger of osteo-articular manifestations, in particular sacroiliitis.
CASE PRESENTATION
METHODS
The case of a boy, affected by acne fulminans and depression, who presented with sacroiliitis after a 10-week treatment with isotretinoin is presented. After SAPHO diagnosis, NSAIDs therapy was started but the onset of bilateral gluteal hidradenitis suppurativa required the switch to a TNF-α antagonist (Adalimumab) with the achievement of a good control of the disease. Despite specific therapy with sertraline, the patient continued to complains severe depression.
CONCLUSIONS
CONCLUSIONS
Our case reports a temporal association between the onset of osteo-articular symptoms and the introduction of isotretinoin, as previously described. However, this timeline is not sufficient to establish a causal role of this drug into the pathogenesis of sacroiliitis. At this regard, further studies are required. The occurrence of hidradenitis suppurativa during SAPHO course supported the introduction of TNF-α blockers with a favourable result, as reported in a few cases in literature. The association between SAPHO syndrome and depressive mood disorders is already reported. Our patient experienced severe depression whose trend seems to be independent from the course of the main disease. Currently, it is not clarified if depression could be considered reactive to the underling disease or if it forms an integral part of the autoinflammatory disorder.
Identifiants
pubmed: 33187546
doi: 10.1186/s13052-020-00933-1
pii: 10.1186/s13052-020-00933-1
pmc: PMC7663872
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Dermatologic Agents
0
Isotretinoin
EH28UP18IF
Adalimumab
FYS6T7F842
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Références
Mod Rheumatol. 2018 May;28(3):432-434
pubmed: 29251057
Am J Clin Dermatol. 2012 Feb 1;13(1):55-9
pubmed: 22007948
Curr Top Med Chem. 2018;18(16):1395-1401
pubmed: 29766809
Rheum Dis Clin North Am. 2013 May;39(2):401-18
pubmed: 23597971
Int J Dermatol. 2018 Jan;57(1):10-18
pubmed: 28884797
SAGE Open Med Case Rep. 2018 Jun 01;6:2050313X18778723
pubmed: 29922466
Rheumatol Int. 2019 Dec;39(12):2159-2165
pubmed: 31455984
Free Radic Res. 2007 Dec;41(12):1338-47
pubmed: 18075836
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:40-41
pubmed: 31535768
J Infect. 2016 Jul 5;72 Suppl:S106-14
pubmed: 27263075
Clin Rheumatol. 2020 Jan;39(1):177-187
pubmed: 31312988
Rheumatology (Oxford). 2016 Jun;55(6):1023-30
pubmed: 26917545
J Rheumatol. 2015 Nov;42(11):2106-9
pubmed: 26472411
Orphanet J Rare Dis. 2017 May 25;12(1):103
pubmed: 28545486
J Adolesc Health. 2014 Aug;55(2):304-6
pubmed: 24726464
Clin Rheumatol. 2017 Sep;36(9):2151-2158
pubmed: 28725947
An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):193-6
pubmed: 24346917
Front Biosci. 2006 Jan 01;11:529-43
pubmed: 16146751
Australas J Dermatol. 2012 Nov;53(4):298-300
pubmed: 23157782
J Am Acad Dermatol. 2017 Jul;77(1):109-117
pubmed: 28619551